Mechanism of MicroRNA-375 Promoter Methylation in Promoting Ovarian Cancer Cell Malignancy.
Adaptor Proteins, Signal Transducing
/ genetics
Animals
Apoptosis
Biomarkers, Tumor
/ genetics
Cell Proliferation
DNA Methylation
Female
Gene Expression Regulation, Neoplastic
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
/ genetics
Ovarian Neoplasms
/ genetics
Prognosis
Promoter Regions, Genetic
Transcription Factors
/ genetics
Tumor Cells, Cultured
Wnt Signaling Pathway
Xenograft Model Antitumor Assays
YAP-Signaling Proteins
Wnt/β-catenin pathway
microRNA-375
ovarian cancer
promoter methylation
yes-associated protein 1
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
30
11
2021
Statut:
ppublish
Résumé
Ovarian cancer (OC) ranks one of the most prevalent fatal tumors of female genital organs. Aberrant promoter methylation triggers changes of microRNA (miR)-375 in OC. Our study aimed to evaluate the mechanism of methylated miR-375 promoter region in OC cell malignancy and to seek the possible treatment for OC. miR-375 promoter methylation level in OC tissues and cells was detected. miR-375 expression in OC tissues and cell lines was compared with that in demethylated cells. Role of miR-375 in OC progression was measured. Dual-luciferase reporter gene assay was utilized to verify the targeting relationship between miR-375 and Yes-associated protein 1 (YAP1). Then, Wnt/β-catenin pathway-related protein expression was tested. Moreover, xenograft transplantation was applied to confirm the Highly methylated miR-375 was seen in OC tissues and cell lines, while its expression was decreased as the promoter methylation increased. Demethylation in OC cells brought miR-375 back to normal level, with obviously declined cell invasion, migration and viability and improved apoptosis. Additionally, miR-375 targeted YAP1 to regulate the Wnt/β-catenin pathway protein expression. Overexpressed YAP1 reversed the protein expression, promoted cell invasion, migration and viability while reduced cell apoptosis. Overexpressed miR-375 Our study demonstrated that demethylated miR-375 inhibited OC growth by targeting YAP1 and downregulating the Wnt/β-catenin pathway. This investigation may offer novel insight for OC treatment.
Identifiants
pubmed: 33928819
doi: 10.1177/1533033820980115
pmc: PMC8113360
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Biomarkers, Tumor
0
MIRN375 microRNA, human
0
MicroRNAs
0
Transcription Factors
0
YAP-Signaling Proteins
0
YAP1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533033820980115Références
Int J Cancer. 2014 Sep 1;135(5):1011-8
pubmed: 24166096
Br J Nurs. 2013 Sep 12-25;22(17):S23-30
pubmed: 24067270
Postepy Hig Med Dosw (Online). 2015 Dec 02;69:1275-90
pubmed: 26671919
J Geriatr Oncol. 2016 Sep;7(5):354-61
pubmed: 27499341
Folia Histochem Cytobiol. 2015;53(2):105-19
pubmed: 26160682
Mol Med Rep. 2017 Aug;16(2):1007-1013
pubmed: 29067442
DNA Cell Biol. 2017 Nov;36(11):983-990
pubmed: 28933561
Oncogene. 2017 Jan 5;36(1):24-34
pubmed: 27270433
Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3223-9
pubmed: 27466996
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:139-152
pubmed: 28111228
Ann Oncol. 2016 Aug;27(8):1449-55
pubmed: 27037296
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14
pubmed: 27743768
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
J Clin Invest. 2017 Jan 3;127(1):137-152
pubmed: 27869648
Oncol Lett. 2017 Jun;13(6):4769-4775
pubmed: 28599478
Indian J Cancer. 2014 Mar;51 Suppl 3:e72-6
pubmed: 25818738
J Ovarian Res. 2019 Jan 22;12(1):6
pubmed: 30670062
Sci Rep. 2019 Mar 1;9(1):3197
pubmed: 30824765
Neoplasma. 2017;64(2):244-252
pubmed: 28043152
Oncol Lett. 2016 Sep;12(3):1821-1825
pubmed: 27588129
PLoS One. 2017 Sep 21;12(9):e0184439
pubmed: 28934230
Genomics. 2020 Jan;112(1):163-168
pubmed: 30189225
Endocr Relat Cancer. 2014 Mar 04;21(2):297-310
pubmed: 24389730
Int J Clin Exp Pathol. 2013 May 15;6(6):1095-102
pubmed: 23696927
Cell Death Dis. 2018 Jan 24;9(2):92
pubmed: 29367737
Genes (Basel). 2018 Jan 08;9(1):
pubmed: 29316729
PLoS One. 2014 Mar 12;9(3):e91770
pubmed: 24622501
Sci Rep. 2017 Aug 18;7(1):8760
pubmed: 28821788
Curr Opin Pharmacol. 2016 Aug;29:26-33
pubmed: 27262779
Cells. 2019 Nov 18;8(11):
pubmed: 31752117
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56
pubmed: 26224579
Biochem Biophys Res Commun. 2010 Apr 9;394(3):623-7
pubmed: 20226166
Gene. 2018 Jul 1;662:28-36
pubmed: 29631007
Physiol Rev. 2014 Oct;94(4):1287-312
pubmed: 25287865
Nat Rev Clin Oncol. 2016 Apr;13(4):255-61
pubmed: 26787282
Cancer Cell. 2006 Jun;9(6):435-43
pubmed: 16766263
Sci Rep. 2017 May 4;7(1):1469
pubmed: 28473707
Int J Gynecol Cancer. 2016 Jun;26(5):851-8
pubmed: 27206217
Biochimie. 2019 Dec;167:12-24
pubmed: 31493469
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301